within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01M_QuinoloneAntibacterials.J01MA25_Lascufloxacin;

model Lascufloxacin
  extends Pharmacolibrary.Drugs.ATC.J.J01MA25;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J01MA25</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Lascufloxacin is a novel fluoroquinolone antibiotic used for the treatment of respiratory tract infections such as community-acquired pneumonia and bronchitis. It demonstrates activity against a broad range of Gram-positive and Gram-negative bacteria and is approved in Japan but not widely globally.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult Japanese subjects following a single oral dose.</p><h4>References</h4><ol><li><p>Furuie, H, et al., &amp; Yoshida, H (2018). Intrapulmonary Pharmacokinetics of Lascufloxacin in Healthy Adult Volunteers. <i>Antimicrobial agents and chemotherapy</i> 62(4) –. DOI:<a href=&quot;https://doi.org/10.1128/AAC.02169-17&quot;>10.1128/AAC.02169-17</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29339391/&quot;>https://pubmed.ncbi.nlm.nih.gov/29339391</a></p></li><li><p>Totsuka, K, et al., &amp; Niwayama, Y (2020). Pharmacokinetic study of lascufloxacin in non-elderly healthy men and elderly men. <i>Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy</i> 26(3) 231–239. DOI:<a href=&quot;https://doi.org/10.1016/j.jiac.2019.09.010&quot;>10.1016/j.jiac.2019.09.010</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31882385/&quot;>https://pubmed.ncbi.nlm.nih.gov/31882385</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Lascufloxacin;
